A phase III study to evaluate Ameluz photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma

Trial Profile

A phase III study to evaluate Ameluz photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Basal cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Biofrontera AG
  • Most Recent Events

    • 27 Dec 2017 New trial record
    • 19 Dec 2017 According to a Biofrontera media release, that the Company has filed an investigational new drug (IND) application with the US FDA for this trial. This trial will support the regulatory submissions to the FDA for the approval of Ameluz for superficial basal cell carcinoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top